Background: Pancreatic fistula is a potentially life-threatening complication after a pancreatic resection. The aim of this systematic review was to evaluate the role of matrix-bound sealants after a pancreatic resection in terms of preventing or ameliorating the course of a post-operative pancreatic fistula.
Methods: A systematic search was performed in the literature from May 2005 to April 2015. Included were clinical studies using matrix-bound sealants after a pancreatic resection, reporting a post-operative pancreatic fistula (POPF) according to the International Study Group on Pancreatic Fistula classification, in which grade B and C fistulae were considered clinically relevant.
Results: Two were studies on patients undergoing pancreatoduodenectomy (sealants n = 67, controls n = 27) and four studies on a distal pancreatectomy (sealants n = 258, controls n = 178). After a pancreatoduodenectomy, 13% of patients treated with sealants versus 11% of patients without sealants developed a POPF (P = 0.76), of which 4% versus 4% were clinically relevant (P = 0.87). After a distal pancreatectomy, 42% of patients treated with sealants versus 52% of patients without sealants developed a POPF (P = 0.03). Of these, 9% versus 12% were clinically relevant (P = 0.19).
Conclusions: The present data do not support the routine use of matrix-bound sealants after a pancreatic resection, as there was no effect on clinically relevant POPF. Larger, well-designed studies are needed to determine the efficacy of sealants in preventing POPF after a pancreatoduodenectomy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605343 | PMC |
http://dx.doi.org/10.1111/hpb.12472 | DOI Listing |
Cancers (Basel)
February 2025
Department of Hepatobiliary and Pancreatic Surgery, Manchester Royal Infirmary Hospital, Manchester M13 9WL, UK.
Aim: The aim of this study was to determine the impact of sarcopenia on outcomes in patients undergoing curative resection for perihilar cholangiocarcinoma.
Methods: A systematic review and meta-analysis following PRISMA standards were conducted, searching for studies comparing patients with and without sarcopenia undergoing surgery for perihilar cholangiocarcinoma. The outcomes included postoperative mortality, Clavien-Dindo ≥ 3 complications, intraoperative blood loss, need for blood transfusion, length of hospital stay, and overall survival (OS) (time-to-event).
Cancers (Basel)
February 2025
Department of General Surgery, Azienda USL of Piacenza, 29121 Piacenza, Italy.
: Neoadjuvant therapy (NAT) improves surgical outcomes in pancreatic cancer, but its role in elderly patients remains unclear. Due to comorbidities and lower chemotherapy tolerance, assessing NAT's benefits and risks in this population is essential. This systematic review assesses the impact of NAT on overall survival (OS), surgical resection rates, and treatment-related toxicities(G3-4) in elderly patients with resectable, borderline, or locally advanced pancreatic cancer.
View Article and Find Full Text PDFBMC Cancer
March 2025
Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100124, China.
Background: The 5-fuorouracil, oxaliplatin and irinotecan (FOLFOXIRI) regimen is the standard first-line treatment for advanced pancreatic cancer (APC). Capecitabine, an oral prodrug of 5-fluorouracil, offers a more convenient and potentially safer alternative. We evaluated the efficacy and safety of the XELOXIRI regimen (capecitabine, oxaliplatin, irinotecan) in Chinese patients with APC.
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
March 2025
Department of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan; Department of Oncology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Background: Randomized trials and meta-analyses have indicated longer survival with neoadjuvant than with adjuvant therapy in patients with resectable or borderline resectable (R/BR) pancreatic adenocarcinoma. Despite the efficacy of chemotherapy, the role of radiotherapy as an adjuvant or neoadjuvant treatment for patients with R/BR pancreatic adenocarcinoma remains unclear. In this systematic review and meta-analysis, we compared the benefits of additional chemoradiotherapy (CRT) to neoadjuvant chemotherapy (NAC) with NAC alone for R/BR pancreatic adenocarcinoma.
View Article and Find Full Text PDFGan To Kagaku Ryoho
February 2025
Dept. of Surgery, Kinan Hospital.
A 75-year-old woman was admitted to our hospital with a complaint of jaundice and elevated liver enzyme levels. She was diagnosed with pancreatic head carcinoma after examination. She had undergone massive resection of the small intestine due to thrombosis of the superior mesenteric artery at 48 years of age, and the remaining ileum was approximately 70 cm in length.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!